Jiangsu Hengrui Pharmaceuticals’ HR20031 Accepted for Review by China’s NMPA for Type 2 Diabetes
Jiangsu Hengrui Pharmaceuticals (SHA: 600276), a leading Chinese pharmaceutical company, has announced that the National...
AstraZeneca’s Imfinzi Gains NMPA Approval for First-Line Cholangiocarcinoma Treatment
The National Medical Products Administration (NMPA) of China has indicated on its website that it...
Hansoh Pharmaceutical’s HS-10511 Tablets for Hypertrophic Cardiomyopathy Cleared for Clinical Trials
Hansoh Pharmaceutical (HKG: 3692) has announced that its affiliated company’s self-developed Class 1 new drug,...
Chiesi Farmaceutici and Shanghai Pharmaceutical Partner on Distribution at CIIE
Among the series of deals secured by multinational corporations at the 6th China International Import...
Bayer Shifts Focus of Recursion Pharmaceuticals Collaboration to Precision Oncology
Germany-headquartered Bayer (ETR: BAYN) has announced a significant modification to its 2020 drug discovery collaboration...
Lizhu Pharmaceutical Cancels ChiNext IPO, Opts for NEEQ Listing for Subsidiary Lizhu Reagent
On November 11, 2023, Lizhu Pharmaceutical (HKG: 1513) announced a strategic shift in its plans...
Novo Nordisk Commits Over DKK 42 Billion to Expand Chronic Disease Production in Denmark
Novo Nordisk (CPH: NOVO-B), a leading pharmaceutical company, last week announced a substantial plan to...
Eli Lilly China’s President Benjamin L. Basil to Depart for Personal Reasons
It has been reported that Benjamin L. Basil, the current president and general manager of...
Clinical Research on rAAV Gene Drug ZS805 for Fabry Disease Launched by Zhishan Weixin
Zhishan Weixin Biotechnology Co., Ltd, a China-based biotech company, has announced the launch of the...
Jiangsu Hengrui Pharmaceuticals’ Subsidiary Shengdi Pharmaceuticals Receives NMPA Approval for HRS-9057
Jiangsu Hengrui Pharmaceuticals (SHA: 600276), a leading pharmaceutical company in China, has announced that its...
Beijing Aosaikang’s Combo Therapy for NSCLC Accepted for Clinical Trial by NMPA
Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755), a Chinese pharmaceutical company, has announced that the...
Lundbeck A/S Reports 7% YOY Revenue Increase in Q3 2023 and 9% Growth for the First Three Quarters
Denmark-based biopharmaceutical company H. Lundbeck A/S (CPH: HLUN-A) has announced its financial results for the...
Sandoz Invests in New Biosimilars and Penicillin API Production Sites in Europe
Switzerland-based pharmaceutical company Sandoz (SWX: SDZ) has announced the opening of two new production sites...
Merck Reports Q3 2023 Financial Results with Mixed Performance Across Segments
Germany-based Merck (ETR: MRK) has released its financial results for the third quarter of 2023,...
AimingMed Partners with Becton, Dickinson and Co. to Advance Tumor Precision Medicine
AimingMed, a leading provider of tumor precision medicine solutions based in Hangzhou, has announced a...
China’s NMPA Grants Conditional Approval for Juventas’ CAR-T Therapy Inaticabtagene Autoleucel
The National Medical Products Administration (NMPA) has conditionally approved the marketing of inaticabtagene autoleucel (CNCT...
China’s NMPA Officially Seeks Membership in the Pharmaceutical Inspection Co-operation Scheme (PIC/S)
The Pharmaceutical Inspection Co-operation Scheme (PIC/S) has announced that China’s National Medical Products Administration (NMPA)...
Eli Lilly’s Zepbound Approved by FDA for Chronic Weight Management in Adults
Eli Lilly (NYSE: LLY) has received registration approval from the US Food and Drug Administration...
BeiGene Ltd Reports Q3 2023 Financial Results with 102% YOY Revenue Increase
BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has released its financial results for the...
Danaher Corporation Partners with CHEA to Boost Oncology Centers in Chinese Counties
US-based science and technology services giant Danaher Corporation (NYSE: DHR) has entered into a partnership...